GLP
How to Adjust Weight Loss Goals on GLP-1 Medications
Adjust weight goals on GLP-1 meds by tracking body composition and labs, optimizing protein, activity, sleep, and working with your provider on dosing.
Falsified Mounjaro pens prompt urgent safety advisory
MHRA warns of counterfeit Mounjaro pens (batch D873576); stop use and check batch numbers for infection risk.
Novo Nordisk shares drop as Alzheimer’s hopes for weight-loss drug fade
Novo Nordisk’s semaglutide failed to slow Alzheimer’s in large trials, prompting shares to fall and expert reactions.
China’s Supreme Court Upholds Semaglutide Patent for Novo Nordisk
China’s Supreme People’s Court upholds Novo Nordisk’s semaglutide compound patent, supporting IP protection.
Over 600,000 Californians Risk Losing Access to GLP-1 Weight-Loss Drugs
California’s Medi-Cal will stop covering GLP-1 weight-loss drugs for weight-loss-only prescriptions, effective Jan. 1, 2026.
Weight-Loss Pill Approval Likely to Prompt Overhaul of Packaged Food and Fast-Food Products
FDA approval of GLP-1 weight-loss pills may prompt food makers and restaurants to shift to high-protein, smaller-portion products.
FDA Approves New Oral Wegovy Pill for 2026, Revolutionizing Semaglutide Administration
Analysis of 2026 semaglutide options: FDA-approved oral Wegovy, injectables, compounded pathways, costs and safety.
How to Taper Off GLP-1 Medications Safely
How to gradually taper GLP-1 meds to curb hunger, prevent rapid weight regain, and stabilize blood sugar with medical guidance, lifestyle changes, and close monitoring.
5 Tools for Tracking GLP-1 Progress
Compare five tools—patient portal, three apps, and printable journals—for logging GLP‑1 injections, weight, injection sites, and side effects to optimize treatment.
